Uniparental disomy and pretreatment IGF-1 may predict elevated IGF-1 levels in Prader-Willi patients on GH treatment.
Adverse effects
Growth hormone therapy
IGF-1
Prader-Willi syndrome
Uniparental disomy
Journal
Growth hormone & IGF research : official journal of the Growth Hormone Research Society and the International IGF Research Society
ISSN: 1532-2238
Titre abrégé: Growth Horm IGF Res
Pays: Scotland
ID NLM: 9814320
Informations de publication
Date de publication:
Historique:
received:
04
05
2019
revised:
09
08
2019
accepted:
26
08
2019
pubmed:
6
9
2019
medline:
13
5
2020
entrez:
6
9
2019
Statut:
ppublish
Résumé
Pediatric patients with Prader-Willi syndrome (PWS) can be treated with recombinant human GH (rhGH). These patients are highly sensitive to rhGH and the standard doses suggested by the international guidelines often result in IGF-1 above the normal range. We aimed to evaluate 1 the proper rhGH dose to optimize auxological outcomes and to avoid potential overtreatment, and 2 which patients are more sensitive to rhGH. In this multicenter real-life study, we recruited 215 patients with PWS older than 1 year, on rhGH at least for 6 months, from Italian Centers for PWS care. We collected auxological parameters, rhGH dose, IGF-1 at recruitment and (when available) at start of treatment. The rhGH dose was 4.3 (0.7/8.4) mg/m
Identifiants
pubmed: 31487604
pii: S1096-6374(19)30040-1
doi: 10.1016/j.ghir.2019.08.003
pii:
doi:
Substances chimiques
IGF1 protein, human
0
Human Growth Hormone
12629-01-5
Insulin-Like Growth Factor I
67763-96-6
Types de publication
Journal Article
Multicenter Study
Observational Study
Langues
eng
Sous-ensembles de citation
IM
Pagination
9-15Informations de copyright
Copyright © 2019 Elsevier Ltd. All rights reserved.